2008-04-21 23:47:24 -
www.accelrys.com - Accelrys Inc. (NASDAQ:ACCL) today announced its intention to support Microsoft's Office SharePoint Server 2007 as a publication platform for Accelrys' scientific applications. In addition, Accelrys will work collaboratively with Microsoft to evaluate Windows HPC Server 2008 and other Microsoft platform products.
"Our collaboration with Microsoft allows Accelrys to deliver scientific capabilities and content to
the broader scientific community via their desktops," said Mark J. Emkjer, president and chief executive officer, Accelrys. "Microsoft's broad reach further enhances the Accelrys ecosystem and expands our market opportunity as it helps us to deploy leading-edge technology that will enable rich scientific collaboration and allow research teams to make more informed decisions."
"Pharmaceutical and biotech companies face significant challenges in both improving the flow of information throughout their organizations and turning large amounts of data into insight," said Rudiger Dorn, worldwide pharmaceutical industry managing director, Microsoft Corp. "Accelrys is a leader in providing tools to assist organizations in the drug discovery and development process, and we're pleased that the company chose to deploy its scientific business intelligence platform solutions on Microsoft's widely supported, familiar and easy-to-use platform."
Initially the SharePoint Server integration will allow Accelrys scientific applications to be executed and displayed from the SharePoint environment through SciTegic Enterprise Server 7.0, the Accelrys scientific business intelligence platform. Accelrys will be demonstrating its scientific capabilities integrated with SharePoint in the Microsoft booth at the upcoming BioIT World Conference, April 28 - 30, 2008, in Boston.
About Accelrys
Accelrys develops and commercializes Scientific Business Intelligence software for the integration, mining, analysis, modeling and simulation, management and interactive reporting of scientific data. Our solutions are used by biologists, chemists, materials scientists, and information technology professionals for product design as well as drug discovery and development. Our technology and services are designed to meet the needs of today's leading research and development organizations including leading commercial, government and academic organizations. For more information about Accelrys, visit its website at
www.accelrys.com/.
Forward-Looking Statements
This press release contains forward-looking statements. Such statements, including statements relating to the potential benefits of the collaboration between Microsoft and Accelrys, benefits to the companies and their customers, are subject to risks and uncertainties including, but not limited to, the risks that the collaboration will not result in benefits or additional sales, and that the companies' products will not be timely or successfully completed, developed or achieve market acceptance, demand relating to these products, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys and Microsoft disclaim any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in their expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Accelrys
Philomena Walsh, 858-799-5440
pwalsh@accelrys.com 
